In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IntelliDx Inc.

Latest From IntelliDx Inc.

The Top Device Stories of 2008

As 2008 draws to a close, In Vivo takes stock of the major events affecting the medical device industry in 2008. Two stories continue to unfold; how the new Obama administration will control national health spending, and the financial crisis that hit the US and global economies. The latter is already taking its toll on medtech. Financial markets crashed, and so did public device companies. M&A dwindled as the year went on, with some notable--and surprising--exceptions, and the downturn is driving VCs to invest either extremely early or late. In other stories: the Department of Justice continued probing into physician conflict of interest matters, this time focusing on the influential Cardiovascular Research Foundation. Also from Washington, the 510(k) process is under review, and 2009 may see changes that make the process of demonstrating safety and effectiveness more costly for device companies. CMS instituted payment reforms affecting hospitals, although this may be good news for medtech companies offering products to help curb hospital-acquired infections and medical errors. The news was good in diabetes--for devices, not pharmaceuticals--with positive outcomes from a major trial on continuous glucose monitoring and two new markets opening up in diabetes for device manufacturers. The regulatory agency delivered some positive news to companies in cardiac rhythm management and neurostimulation too. And second generation drug-eluting stents found a market more receptive than it was a year ago.
Medical Device Business Strategies

Edwards Lifesciences and Dexcom Join Forces in New Critical Care Growth Market

A new market in hospital intensive care units has opened up for companies glucose monitoring technologies and it represents a double-digit growth opportunity both for companies with continuous glucose monitors and critical care franchises. As partners,, Edwards Lifesciences and Dexcom bring both the marketing and technological strengths to successfully compete in this new market.
Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Glucose Testing
  • Medical Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • IntelliDx Inc.
  • Senior Management
  • Gary Stroy, Pres. & CEO
  • Contact Info
  • IntelliDx Inc.
    Phone: (650) 704-8927
    Santa Clara, CA
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register